To understand the extent of this success, patients with Diffuse Large B-Cell Lymphoma (DLBCL) and Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL), when treated with Tisagenlecleucel, an FDA-approved CAR T-cell product for CD19+ B-cells, achieved an objective response rate (ORR) of 52% and 81%, respectively (18, 19). Here, CD19 is linked to diffuse large B-cell lymphoma.